The Potential Value of Clostridium Difficile Vaccine: an Economic Computer Simulation Model

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2010 Jun 15

PMID 20541582

Citations 20

Authors

Bruce Y Lee

Michael J Popovich

Ye Tian

Rachel R Bailey

Paul J Ufberg

Ann E Wiringa

Robert R Muder

Affiliations

Soon will be listed here.

Abstract

Efforts are currently underway to develop a vaccine against Clostridium difficile infection (CDI). We developed two decision analytic Monte Carlo computer simulation models: (1) an Initial Prevention Model depicting the decision whether to administer C. difficile vaccine to patients at-risk for CDI and (2) a Recurrence Prevention Model depicting the decision whether to administer C. difficile vaccine to prevent CDI recurrence. Our results suggest that a C. difficile vaccine could be cost-effective over a wide range of C. difficile risk, vaccine costs, and vaccine efficacies especially, when being used post-CDI treatment to prevent recurrent disease.

Citing Articles

Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against Infection.

Wang S, Heuler J, Bullock J, Qin J, Chakraborty S, Nathaniel A Vaccines (Basel). 2025; 13(1).

PMID: 39852800 PMC: 11768939. DOI: 10.3390/vaccines13010021.

infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.

Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffre M Clin Microbiol Rev. 2024; 37(2):e0013523.

PMID: 38421181 PMC: 11324037. DOI: 10.1128/cmr.00135-23.

Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.

Wang S, Zhu D, Sun X Microbiol Spectr. 2022; 10(3):e0026322.

PMID: 35583336 PMC: 9241731. DOI: 10.1128/spectrum.00263-22.

Modeling the potential impact of administering vaccines against Clostridioides difficile infection to individuals in healthcare facilities.

Toth D, Keegan L, Samore M, Khader K, OHagan J, Yu H Vaccine. 2020; 38(37):5927-5932.

PMID: 32703744 PMC: 7898464. DOI: 10.1016/j.vaccine.2020.06.081.

Molecular features of lipoprotein CD0873: A potential vaccine against the human pathogen .

Bradshaw W, Bruxelle J, Kovacs-Simon A, Harmer N, Janoir C, Pechine S J Biol Chem. 2019; 294(43):15850-15861.

PMID: 31420448 PMC: 6816091. DOI: 10.1074/jbc.RA119.010120.

References

Shim J, Johnson S, Samore M, Bliss D, Gerding D . Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998; 351(9103):633-6. DOI: 10.1016/S0140-6736(97)08062-8. View

Rubin M, Bodenstein L, Kent K . Severe Clostridium difficile colitis. Dis Colon Rectum. 1995; 38(4):350-4. DOI: 10.1007/BF02054220. View

Pepin J, Alary M, Valiquette L, Raiche E, Ruel J, Fulop K . Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40(11):1591-7. DOI: 10.1086/430315. View

Olson M, Shanholtzer C, Lee Jr J, Gerding D . Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994; 15(6):371-81. DOI: 10.1086/646934. View

FEKETY R, McFarland L, Surawicz C, Greenberg R, Elmer G, Mulligan M . Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997; 24(3):324-33. DOI: 10.1093/clinids/24.3.324. View

Nair S, Yadav D, Corpuz M, Pitchumoni C . Clostridium difficile colitis: factors influencing treatment failure and relapse--a prospective evaluation. Am J Gastroenterol. 1998; 93(10):1873-6. DOI: 10.1111/j.1572-0241.1998.00541.x. View

Young G, Ward P, Bayley N, Gordon D, Higgins G, Trapani J . Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985; 89(5):1038-45. DOI: 10.1016/0016-5085(85)90206-9. View

Hull M, Beck P . Clostridium difficile-associated colitis. Can Fam Physician. 2004; 50:1536-40, 1543-5. PMC: 2214524. View

Ni Eidhin D, OBrien J, McCabe M, Athie-Morales V, Kelleher D . Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol. 2007; 52(2):207-18. DOI: 10.1111/j.1574-695X.2007.00363.x. View

10.

McFarland L . Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008; 5(1):40-8. DOI: 10.1038/ncpgasthep1029. View

11.

Cross A, Chen W, Levine M . A case for immunization against nosocomial infections. J Leukoc Biol. 2007; 83(3):483-8. DOI: 10.1189/jlb.0607379. View

12.

Kelly C, Lamont J . Clostridium difficile--more difficult than ever. N Engl J Med. 2008; 359(18):1932-40. DOI: 10.1056/NEJMra0707500. View

13.

Dubberke E, Butler A, Reske K, Agniel D, Olsen M, DAngelo G . Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis. 2008; 14(7):1031-8. PMC: 2600322. DOI: 10.3201/eid1407.070867. View

14.

Miller M, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M . Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol. 2002; 23(3):137-40. DOI: 10.1086/502023. View

15.

Koss K, Clark M, Sanders D, Morton D, Keighley M, Goh J . The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006; 8(2):149-54. DOI: 10.1111/j.1463-1318.2005.00876.x. View

16.

Hermsen J, Dobrescu C, Kudsk K . Clostridium difficile infection: a surgical disease in evolution. J Gastrointest Surg. 2008; 12(9):1512-7. DOI: 10.1007/s11605-008-0569-9. View

17.

Byrn J, Maun D, Gingold D, Baril D, Ozao J, Divino C . Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg. 2008; 143(2):150-4. DOI: 10.1001/archsurg.2007.46. View

18.

Belmares J, Gerding D, Parada J, Miskevics S, Weaver F, Johnson S . Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007; 55(6):495-501. DOI: 10.1016/j.jinf.2007.09.015. View

19.

Musher D, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F . Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005; 40(11):1586-90. DOI: 10.1086/430311. View

20.

Dudley M, McLAUGHLIN J, Carrington G, Frick J, Nightingale C, Quintiliani R . Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986; 146(6):1101-4. View